Research and experimental development on natural sciences and engineering
ALDEN CANCER THERAPY AS
Operating profit
NOK −1.9m
Equity
NOK −2.8m
Incorporated
2013
Share capital
NOK 47,000
Key figures · 2024
Current ratio
52.07
Equity ratio
-154.1%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Return on assets (%%) | -104.5% | |
| Likviditet | ||
| Current ratio | 52.07 | |
| Working capital | 1.2m | |
| Soliditet | ||
| Equity ratio (%%) | -154.1% | |
| Debt-to-equity ratio | -1.65 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.